Pharming Reports Q3 Revenue Growth of 20.9% and Updates 2026 Guidance
Pharming (PHAR) reported third-quarter revenue of $117.6 million, representing a year-over-year increase of 20.9%. The company's quarterly performance demonstrates strong top-line momentum compared to the previous year. Looking ahead, Pharming has tightened its full-year 2026 total revenue guidance to a range of $380 million to $390 million, slightly narrowing the previous projection of $375 million to $395 million. Additionally, the company lowered its total operating expense guidance to a range between $310 million and [amount not specified in text].
Tickers: $PHAR
Topics: Financial Guidance Operating Expenses Quarterly Earnings Revenue Growth
Read the full article at Seeking Alpha
Part of the story Meta Reports Q3 2026 Revenue Growth Amid Legal Settlement and Massive AI Infrastructure Investment (16 articles)